Emitents | Olainfarm, AS (213800WCG52W62ENOP27) |
Veids | Citi |
Valoda | EN |
Statuss | Publicēts |
Versija | |
Datums | 2013-12-19 17:18:23 |
Versijas komentārs | |
Teksts |
Olaine, 2013.gada 19.decembrī
„Olainfarm” Plans Its 2013
Profit to be at 8.8 Million Lats
Updated financial guidance of AS “Olainfarm” provides that
unconsolidated sales of the company in 2013 will reach 45.4 million
lats (64.6 million euro), while consolidated sales will be as high
as 52.8 million lats (75.1 million euro. Consolidated profit
is expected to be at 8.8 million lats (12.5 million euro), while
unconsolidated profit will reach 7.5 million lats.
Initial
financial guidance was approved on April 12, 2013, they were
revised and presented in December 10, during the webinar conference
hosted by Salvis Lapins, member of company’s Management Board.
Financial guidance was adjusted after more precise data became
available on November sales. Although the sales in November
were rather good, they were still too small to reasonably expect
that the initial financial targets will be
attained.
Since sales of
AS „Olainfarm” have a rather clear seasonality, and traditionally
it is third and fourth quarters, especially November and December
when sales are particularly and sometimes unusually high, the
probability of actually reaching the initial guidance remained
reasonable up until when November sales figures became apparent.
Although sales to Ukraine were improved significantly, bigger sales
improvements to other countries were required in order to reach the
initial financial targets.
Since AS
„Olainfarm” is a company with a large base of employees and fixed
assets, its has a comparatively high break-even point. It implies
that when company’s sales are growing, its profits grow
disproportionally and also, when company’s sales are not reaching
the expected levels, the profit is also corrected
disproportionally. Therefore profit guidance of AS „Olainfarm” for
2013 has been reduced by a bigger factor than the sales guidance.
A/s OlainFarm is one of the
biggest pharmaceutical companies in Latvia with 40 years of
experience in production of medication and chemical and
pharmaceutical products. A basic principle of company's operations
is to produce reliable and effective top quality products for
Latvia and the rest of the world. Products made by the Group are
being exported to more than 30 countries of the world, including
the Baltics, Russia, other CIS, Europe, Asia, North America and
Australia. Information
prepared by:
|
Pielikumi |
|